{"id":"W2692549261","doi":"10.1200/jco.2017.35.15_suppl.e12534","title":"Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Pfizer (Canada); Hôpital du Saint-Sacrement; Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Hazard ratio; Gastroenterology; Palbociclib; Expanded access; Surgery; Toxicity; Cancer; Breast cancer; Metastatic breast cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00115519,0.0004660622,0.002402013,0.0002167711,0.0003488529,0.00003516428,0.0008168508,0.0003110259,0.00005927927],"category_scores_gemma":[0.001683131,0.0002652096,0.0002935981,0.0002711128,0.001296927,0.0006382944,0.0001218345,0.001132995,5.001379e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001237645,"about_ca_system_score_gemma":0.004648413,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03258354,"about_ca_topic_score_gemma":0.2896094,"domain_scores_codex":[0.9948726,0.0005195153,0.002712993,0.0005150607,0.0006953435,0.0006844631],"domain_scores_gemma":[0.9887412,0.001331107,0.006197451,0.0005650316,0.002625952,0.0005392358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3254085,0.003650903,0.3957605,0.000137137,0.002064022,0.00006254776,0.001751237,0.0003146796,0.001374321,0.0000732535,0.0001188349,0.269284],"study_design_scores_gemma":[0.09225549,0.03054481,0.8690707,0.0008060008,0.0001924718,0.00005190054,0.0002067385,0.00003403684,0.004260378,0.0001743154,0.002098127,0.0003050386],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983355,0.00023782,0.00005651813,0.01151526,0.0004138093,0.002972114,0.001201229,0.00001357236,0.0002347063],"genre_scores_gemma":[0.993662,0.001050751,0.003938335,0.0005504325,0.0003886336,0.0001799814,0.00007097888,0.00007660135,0.00008229072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4733102,"threshold_uncertainty_score":0.99998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0559032773756887,"score_gpt":0.4206166147625556,"score_spread":0.364713337386867,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}